NEW DELHI: Mumbai-based Ciplahas reported a 30% year-on-year (YoY) increase in net profit, standing at Rs 1,222 crore for the fourth quarter ended March 31. The company’s revenue was Rs 6,730 crore, reflecting a 9% growth from the corresponding period last year.For FY25, Cipla’s revenue rose 8% to Rs 27,548 crore.Umang Vohra, MD and Global CEO, Cipla, commented on the implications of recent US policies in a post results’ call, stating, “We don’t see any material impact of tariffs on generics as of now.”Regarding Trump’s executive order announced on May 12, he noted, “as of now, we understand that it’s largely targeted at branded drugs. From a generic perspective, generic prices in the US are already significantly comparable with the rest of the world, and even lower in some cases.”Elaborating on the company’s performance, he said, “I am pleased to share that we continue to make considerable progress across our focused markets. In FY25, we recorded a revenue growthof 8% over last year with the EBITDA margin of 25.9%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 7% YoY. Key therapies in branded prescription business continued to outpace the market growth, trade generics business growth trajectory is back on track and anchor brands of consumer health business maintained leadership position. With a positive traction in our differentiated assets, the US business posted an all-time high annual revenue of $934 million.Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front.”
